Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 50 min ago
Peer-reviewedCC BYJournal of Vascular Surgery: Venous and Lymphatic Disorders

Pelvic vein embolization using different embolic agents for the treatment of pelvic venous insufficiency: A systematic review and meta-analysis

4 affiliations
  1. 1Department of Vascular Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Correspondence: Felix Strobl, MD, Department of Vascular Surgery, Charité Universitätsmedizin Berlin, Klinik für Gefäßchirurgie Hindenburgdamm 30, Berlin 12203, Germany
  2. 2Department of Surgery, Experimental Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
  3. 3Department of Vascular Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
  4. 4Department of Radiology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

Abstract

Objective: Embolization of insufficient pelvic veins has been established as the standard first-line therapy in women with chronic pain due to pelvic venous disorder; however, the clinically available embolic devices vary widely, with coils, vascular plugs, glue, and sclerosants or combinations of these devices being the most common. This study aims to evaluate the ability of different devices to reduce pain and their individual rates of success and complications. Methods: A systematic search was conducted using PubMed, ScienceDirect, Cochrane, and ClinicalTrials.gov for studies published on the embolization of insufficient pelvic veins up until November 2025. The primary outcome measure was the effect of embolization on pelvic pain as measured using visual analog scale (VAS). The secondary end points were the technical and clinical success rates as well as the recurrence, complication, and reintervention rates. Results: A total of 28 studies met the inclusion criteria, totaling 2688 patients across 34 individual cohorts who were grouped into five treatment categories. The technical success rate was high across all the embolization methods, ranging from 98.6% to 100%, and the clinical success rate ranged from 68.3% to 100%. All the endovascular treatment options led to a reduction in pain as measured using VAS, which ranged from 4.67 (95% confidence interval [CI], 3.87-5.47) points reduction in the sclerosant-only group to 6.12 (95% CI, 5.46-6.78) in the vascular plugs group. The clinical success rate was the highest in the sclerosant-only and plugs groups at 97.5% (95% CI, 93.7-99.3) and 94.7% (95% CI, 86.9-98.5), respectively. Complications, especially in the form of device migration, most frequently appeared in the coils group at 2.63% (95% CI, 1.76-3.78) and least frequently in the sclerosant-only group at 0.45% (95% CI, 0.01-2.48). Sclerosants led to the lowest recurrence at 1.69% (95% CI, 0.49-4.87) but the highest number of reinterventions at 13.3% (95% CI, 5.1-26.8). Vascular plugs resulted in few complications (0.6% [95% CI, 0.07-2.15]), as well as low recurrence (3.47% [95% CI, 1.6-6.49]) and reintervention (2.59% [95% CI, 1.12-5.04]). Conclusions: All the embolization methods showed excellent technical success rates and marked reduction in pain as measured using VAS. Using coils seems to be associated with the highest occurrence of device migration. The vascular plugs and sclerosant-only groups had high clinical success with low complication rates. Due to the small sample sizes and lack of inter-group comparisons, the conclusions should be viewed cautiously.

Related

  1. Post-embolization dynamic changes in Obsidio Conformable Embolic: volume and radiodensity analysis.
    Mohamad Harraka, Radhika Amin, Amir Pourmorteza +8
    CVIR endovascularPeer-reviewedCC BYFull textHuman geneticsEurope PMCDOAJ
  2. Middle Meningeal Artery Embolization Using Non-Adhesive Liquid Embolic Agents for Chronic Resistant Migraine: Interim Feasibility and Safety Analysis of a Prospective Single-Arm Trial
    Andrey Petrov, Ruslan Sharshebaev, Gulmira Biialieva +6
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Full textPsychiatry & mental healthCrossrefEurope PMC
  3. Efficacy and safety of bronchial artery embolization in the treatment of hemoptysis:a systematic review and meta-analysis of RCTs
    Minhui Zhang, Junchen Wang, Yunyun Shuai +5
    Frontiers in MedicinePeer-reviewedCC BY 4.0Full textHuman geneticsPMC
  4. Efficacy of different acupuncture and moxibustion techniques combined with modern rehabilitation in the treatment of post-stroke dysphagia: systematic evaluation and network meta-analysis of randomized controlled trials
    Hongxu Pei, Xiangxin Zeng, Mijia Guo +1
    Frontiers in NeurologyPeer-reviewedCC BY 4.0NeurologyCrossref
  5. Impact of different treatment regimens on long-term prognosis in patients with proliferative diabetic retinopathy: a systematic review
    Yu-Man Li, Feng Zhao, Wen-Tao Li +2
    International Journal of OphthalmologyPeer-reviewedCC BY-NC-NDFull textGeneral medicinePMC
BibTeX
@article{felixstrobl2026pelvic,
  title = {{Pelvic vein embolization using different embolic agents for the treatment of pelvic venous insufficiency: A systematic review and meta-analysis}},
  author = {Felix Strobl, MD and Agnes Klara Böhm, MD and Lorenz Mertens, MD and Maximilian de Bucourt, MD and Jan Paul Frese, MD and Houman Jalaie, MD and Andreas Greiner, MD and Leon Bruder, MD},
  journal = {Journal of Vascular Surgery: Venous and Lymphatic Disorders},
  year = {2026},
  month = nov,
  doi = {10.1016/j.jvsv.2026.102599},
  url = {https://doi.org/10.1016/j.jvsv.2026.102599},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Pelvic vein embolization using different embolic agents for the treatment of pelvic venous insufficiency: A systematic review and meta-analysis
AU  - Felix Strobl, MD
AU  - Agnes Klara Böhm, MD
AU  - Lorenz Mertens, MD
AU  - Maximilian de Bucourt, MD
AU  - Jan Paul Frese, MD
AU  - Houman Jalaie, MD
AU  - Andreas Greiner, MD
AU  - Leon Bruder, MD
PY  - 2026
DA  - 2026/11/11
JO  - Journal of Vascular Surgery: Venous and Lymphatic Disorders
DO  - 10.1016/j.jvsv.2026.102599
UR  - https://doi.org/10.1016/j.jvsv.2026.102599
AB  - Objective: Embolization of insufficient pelvic veins has been established as the standard first-line therapy in women with chronic pain due to pelvic venous disorder; however, the clinically available embolic devices vary widely, with coils, vascular plugs, glue, and sclerosants or combinations of these devices being the most common. This study aims to evaluate the ability of different devices to reduce pain and their individual rates of success and complications. Methods: A systematic search was conducted using PubMed, ScienceDirect, Cochrane, and ClinicalTrials.gov for studies published on the embolization of insufficient pelvic veins up until November 2025. The primary outcome measure was the effect of embolization on pelvic pain as measured using visual analog scale (VAS). The secondary end points were the technical and clinical success rates as well as the recurrence, complication, and reintervention rates. Results: A total of 28 studies met the inclusion criteria, totaling 2688 patients across 34 individual cohorts who were grouped into five treatment categories. The technical success rate was high across all the embolization methods, ranging from 98.6% to 100%, and the clinical success rate ranged from 68.3% to 100%. All the endovascular treatment options led to a reduction in pain as measured using VAS, which ranged from 4.67 (95% confidence interval [CI], 3.87-5.47) points reduction in the sclerosant-only group to 6.12 (95% CI, 5.46-6.78) in the vascular plugs group. The clinical success rate was the highest in the sclerosant-only and plugs groups at 97.5% (95% CI, 93.7-99.3) and 94.7% (95% CI, 86.9-98.5), respectively. Complications, especially in the form of device migration, most frequently appeared in the coils group at 2.63% (95% CI, 1.76-3.78) and least frequently in the sclerosant-only group at 0.45% (95% CI, 0.01-2.48). Sclerosants led to the lowest recurrence at 1.69% (95% CI, 0.49-4.87) but the highest number of reinterventions at 13.3% (95% CI, 5.1-26.8). Vascular plugs resulted in few complications (0.6% [95% CI, 0.07-2.15]), as well as low recurrence (3.47% [95% CI, 1.6-6.49]) and reintervention (2.59% [95% CI, 1.12-5.04]). Conclusions: All the embolization methods showed excellent technical success rates and marked reduction in pain as measured using VAS. Using coils seems to be associated with the highest occurrence of device migration. The vascular plugs and sclerosant-only groups had high clinical success with low complication rates. Due to the small sample sizes and lack of inter-group comparisons, the conclusions should be viewed cautiously.
SN  - 2213-3348
ER  -